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ABSTRACT
Objective: In this observational study we addressed accelerated arteriosclerosis (AS) in patients with chronic
renal failure (CRF) on hemodialysis (HD) by measuring vascular stiffness (VS) parameters and attempted
to relate them to pro-inflammatory and protective factors. Patients: 96 consecutive patients receiving
regular HD were included. 20 adult patients without major renal, cardiovascular or metabolic morbidities
served as controls. Methods: AS parameters (carotid-femoral pulse wave velocity – PWV, aortic
augmentation index – Aix) were measured by using applanation tonometry (SphygmoCor, AtCor Medical,
Sidney). In addition to routine laboratory tests 25(OH) vitamin D3 (vitamin D3) and high-sensitivity C-
reactive protein (hsCRP) were quantified by immunometric assay; whereas fetuin-A, a-Klotho, tumor
necrosis factor-a (TNF-a) and transforming growth factor-b1 (TGF-b1) were determined by ELISA. Re-
sults: Pro-inflammatory biomarkers (hsCRP, TNF-a and TGF-b1) were markedly elevated (P < 0.01), while
anti-inflammatory factors (fetuin-A: P < 0.05, a-Klotho: P < 0.01, vitamin D3: P < 0.01) significantly
depressed in HD patients when compared to controls. PWV was significantly affected only by total
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cholesterol, fetuin-A and dialysis time. Multiple linear regression analyses revealed that several clinical and
laboratory parameters were associated with pro- and anti-inflammatory biomarkers rather than VS. The
impact of baseline clinical and biochemical variables on outcome measures were also analyzed after three-
year follow-up, and it was demonstrated that low levels of vitamin D, a-Klotho protein and fetuin-A were
related to adverse cardiovascular outcomes, whereas all-cause mortality was associated with elevated hsCRP
and depressed vitamin D. Conclusions: Our results provide additional information on the pathomechanism
of accelerated AS in patients with CRF, and documented direct influence of pro- and anti-inflammatory
biomarkers on major outcome measures.
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INTRODUCTION
The concept of accelerated arteriosclerosis (AS) has been well-established in patients with
chronic renal failure (CRF) with much higher incidence of cardiovascular complications
observed in these patients than those in the general population even after adjustment for
traditional cardiovascular risk factors [1, 2].
Although the underlying mechanism of the initiation and progression of cardiovascular
diseases has not been clearly defined, the contribution of non-traditional risk factors including
low-grade inflammation [3], oxidative stress, endothelial dysfunction, advanced glycation end-
products and dysregulated mineral metabolism has been documented [4].
Experimental and clinical evidences indicate that vascular calcification (VC) plays an
essential role in the development of cardiovascular diseases in CRF patients. VC is an
active, cell-mediated process that includes vascular smooth muscle cells (VSMC) and
endothelial cells [5, 6]. The interaction between endothelium and VSMCs regulates the
progression of VC.
The involvement of endothelium in VC is supported by the findings that endothelin and
vascular endothelial growth factor accelerate, whereas nitrogen oxide attenuates calcification
[7].
Vascular stiffness (VS) is a clinical marker of arteriosclerotic damage and an independent
predictor of fatal and non-fatal cardiovascular events in the general population, in elderly
subjects and in patients with hypertension, diabetes mellitus and end-stage renal diseases
(ESRD) [8].
The present study was undertaken to assess the extent and severity of arteriosclerotic lesion
in CRF patients receiving regular hemodialysis (HD). Attempts were also made to relate VS
parameters to pro-inflammatory markers (high-sensitivity C-reactive protein (hsCRP), tumor
necrosis factor-a (TNF-a), transforming growth factor-b1 (TGF-b1)) and to well-established
protective factors (a-Klotho protein, fetuin-A, vitamin D3) to reveal their contribution to the
cardiovascular compromise. After baseline evaluation all patients were followed up for three
years to analyze the association between outcome measures (cardiovascular events/mortality, all-
cause mortality) and clinical/biochemical variables.
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PATIENTS AND METHODS
Patients
96 (49 male, 47 female) consecutive chronic HD patients in stable clinical condition treated in 2
dialysis centers were enrolled in this observational study. Patients having lower extremity
amputation, any acute infection, malignancy, acute myocardial infarction, pulmonary edema or
hemodynamic instability were excluded from the study.
The underlying renal pathologies that progressed to ESRD were the following: diabetic
nephropathy (24%), benign nephrosclerosis (26%), chronic glomerulonephritis (14%), polycystic
kidney disease (16%), chronic interstitial nephritis (8%), renovascular disease (1%) and other/
unknown causes (11%). Most of the patients (84) received antihypertensive therapy.
The patients underwent 3 HD sessions per week, each having a duration of 4 hours. On-line
hemodiafiltration was carried out by using Fresenius 5008 B equipment with Helixone/Fresenius
polysulfone high-flux dialyzer membranes.
20 adult patients without major renal, cardiovascular or metabolic morbidities served as
control for the analysis of biochemical parameters. Results presented are predialysis values. Body
mass index (BMI) was calculated.
Blood pressure and pulse wave velocity (PWV) measurements
Blood pressure was measured using calibrated automated devices with appropriate cuff sizes.
The results presented here are predialysis values. Pulse pressure and mean arterial pressure were
calculated.
Carotid-femoral pulse wave velocity (cfPWV) and augmentation index (Alx) were measured
using applanation tonometry (SphygmoCor system, AtCor Medical Australia). Measurements
were performed before HD sessions in supine position after an at least 10-min rest in a quiet,
temperature-controlled room. Pulse wave recordings were performed consecutively at two su-
perficial artery sites (carotid-femoral segment). The cfPWV was calculated.
Laboratory measurements
Routine bichemical parameters were measured by standard methods (Table 1). The serum
concentrations of fetuin-A, a-Klotho, TNF-a, TGF-b1 were measured by sandwich enzyme
immunoassays (ELISA) (IBL International Gmbh, Hamburg, Germany and BioVendol Labo-
ratory Med. Inc Brno, Czech Republic). The respective intraassay CVs ranged from 4.8 to 5.5%,
2.7–3.5%, 2.0–14.9%, and 1% (mean), whereas the interassay CVs ranged from 5.7 to 6.8%, 2.9–
11.4%, 4.1–14.0%, and 7.5% (mean). hsCRP and vitamin D3 were determined by immunometric
assay.
Statistical analysis
Statistical analyses were performed using SPSS 21.0 software (SPSS, Inc., Chicago, IL, USA).
Normality of distribution of data was tested by Kolmogorov-Smirnov test. Non-normally
distributed parameters were transformed logarithmically. Correlations between continuous
variables were assessed by linear regression using Pearson's test. Comparison of clinical and
laboratory parameters was made by Student t-test and ANOVA, as appropriate. Data were
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expressed as mean ± SD in case of normal distribution, and median (lower/upper quartile) in
case of non-normal distribution. Backward multiple regression analyses were performed to
determine the relative contribution of selected independent variables in the constructed models
to the variance of the dependent variable. Values of P < 0.05 were considered statistically
significant.
Ethical considerations
The research was approved by the Regional Ethical Committee. The investigation conforms to
the principles outlined in the World Medical Association Declaration of Helsinki. Informed
written consent was obtained from all participants.
RESULTS
Pro-inflammatory (pro-calcigenic) biomarkers (hsCRP, TNF-a, TGF-b1) were markedly
elevated (P < 0.01), whereas anti-inflammatory (anti-atherosclerotic) factors (fetuin-A: P < 0.05,
a-Klotho: P < 0.01, vitamin D3 P < 0.01) significantly depressed when compared to healthy
adults (Table 2).
Univariate linear regression analyses carried out to reveal the association of AS with the
clinical and laboratory parameters have shown that cfPWV correlated positively with Alx (r 5
0.237, P < 0.05), total cholesterol (r 5 0.244, P < 0.05) and fetuin-A (r 5 0.282, P < 0.05) but
inversely with the time spent on HD (r5 0.262, P < 0.05). cfPWV appeared to be independent
of all other variables studied (Table 3).
Table 1. Clinical and laboratory characteristics of the 96 chronic hemodialysis patients
Anthropometric data Biochemical data
Age (years) 65.06 ± 14.09 Creatinine (mmol/l) 683.84 ± 209.61
Height (cm) 162.97 ± 12.04 BUN (mmol/l) 19.47 ± 5.31
Body weight (kg) 72.21 ± 17.87 spKt/V 1.64 ± 0.34
Body mass index (kg/m2) 26.78 ± 6.03 Hemoglobin (g/l) 115.52 ± 12.94
Dialysis vintage (months) 54.48 ± 42.26 Albumin (g/l) 40.38 ± 5.58
SBP (mmHg) 140.21 ± 18.36 Total cholesterol (mmol/l) 4.69 ± 1.24
DBP (mmHg) 80.32 ± 9.87 LDL cholesterol (mmol/l) 2.95 ± 1.04
Pulse pressure (mmHg) 62.58 ± 18.37 HDL cholesterol (mmol/l) 1.08 ± 0.34
MAP (mmHg) 96.6 ± 11.84 Triglyceride (mmol/l) 1.55 ± 1.23
AIx 29.85 ± 10.33 Sodium (mmol/l) 139.53 ± 2.26
PWV (m/s) 8.31 ± 2.38 Potassium (mmol/l) 4.9 ± 0.63
Central SBP (mmHg) 123.61 ± 18.30 Calcium (mmol/l) 2.29 ± 0.34
Central DBP (mmHg) 80.21 ± 8.79 Phosphate (mmol/l) 1.65 ± 0.49
Central pulse pressure (mmHg) 47.74 ± 15.27 Alkaline phosphatase (IU/l) 100.8 ± 44.04
iPTH (pmol/l) 29.96 ± 16.12
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; PWV, carotid-
femoral pulse wave velocity; BUN, blood urea nitrogen; spKt/v, single pool Kt/V; LDL cholesterol, low-
density lipoprotein cholesterol; HDL cholesterol, high-density lipoporotein cholesterol; iPTH, intact
parathyroid hormone.
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Further analysis to explore the contribution of various clinical and laboratory factors to the
variance of VS parameters was made by applying multiple regression models. These included
Alx as a dependent variable, and cfPWV, central augmentation pressure, central systolic blood
pressure, central pulse pressure, Kt/V and parathyroid hormone as independent varibles. Only
central augmentation pressure (b5 1.318, P < 0.000) and central pulse pressure (b5 0.71, P <
0.00) had significant contribution. cfPWV as dependent variable was significantly affected by
fetuin-A (b 5 0.24, P < 0.03) and dialysis time (b 5 0.23, P < 0.04).
Multiple linear regression models were also applied to establish independent variables that
have significant impact on the pro- and anti-inflammatory biomarkers studied. Out of the pro-
inflammatory markers, the variance of hsCRP was negatively influenced by plasma vitamin D3
(b 5 0.23, P < 0.01), sodium (b 5 0.26, P < 0.00) and albumin levels (b 5 0.36, P < 0.00)
and positively by BMI (b 5 0.76, P < 0.00). TNFa and TGF-b1 as dependent variables were
found to correlate significantly only with a-Klotho (b 5 0.41, P < 0.00) and plasma creatinine
(b 5 0.30, P < 0.003), as well as with fetuin-A (b 5 0.24, P < 0.02) and plasma albumin
(b 5 0.33, P < 0.002), respectively.
Analysis of protective factors by applying this multiple regression model revealed significant
negative association of fetuin-A with age (b 5 0.225, P < 0.05), TGF-b1 (b 5 0.228, P <
0.02), and dialysis time (b 5 0.26, P < 0.01), whereas a positive relationship was found be-
tween fetuin-A and triglyceride levels (b 5 0.43, P < 0.00). a-Klotho as dependent variable
correlated positively with TNF-a (b 5 0.44, P < 0.00) and negatively with plasma calcium (b 5
0.24, P < 0.01).
During the follow-up period of three years 25 patients (26.6%) encountered cardiovascular
events that requited hospital admission. 11 patients (11.7%) died due to cardiovascular pa-
thologies and the all-cause mortality accounted to 31 patients (33.0%).
Patients with cardiovascular events were older and had significantly depressed serum levels
of vitamin D, a-Klotho protein and fetuin-A than those without these pathologies. Cardio-
vascular parameters, inflammatory markers and routine laboratory tests proved to be similar in
the two groups. Essentially the same results were seen when patients with and without car-
diovascular death were compared. All-cause mortality was also associated with older age and
markedly reduced vitamin D levels, but they had elevated hsCRP. These findings strongly
suggest that vitamin D depletion and inflammation may play a major role in adverse cardio-
vascular outcomes in uremic patients on HD (Table 4).
Table 2. Plasma levels of pro- and anti-inflammatory and calcigenic factors in end-stage renal failure













Patients 11.4 ± 7.5 0.43 ± 0.11 299.3 ± 124.7 20.2 ± 15.9 2.85 ± 1.35 11.8 ± 10.4
Controls 52.2 ± 13.1 0.55 ± 0.09 602 ± 100 5.2 ± 1.3 0.69 ± 0.42 4.51 ± 5.31
P 0.001 0.05 0.01 0.01 0.00 0.01
TNF-a: tumor necrosis factor-a, TGFb-1: transforming growth factorb-1, hsCRP: high-sensitivity C-
reactive protein.
*P < 0.05 is considered statistically significant.
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Table 3. Correlation of carotid-femoral pulse wave velocity and clinical-laboratory variables using
univariable linear regression analysis among 96 chronic hemodialysis patients
Variable R value P value
Age (years) 0.214 0.058
Dialysis time (months) 0.262* 0.019
Height (cm) 0.060 0.600
Body weight (kg) 0.230* 0.042
BMI (kg/m2) 0.196 0.084
Vitamin D (nmol/l) 0.203 0.073
iPTH (pmol/l) 0.012 0.919
Fetuin A (g/l) 0.282* 0.012
a-Klotho (pg/ml) 0.016 0.886
TNF-a (pg/ml) 0.177 0.163
TGFb-1 (ng/ml) 0.093 0.456
Augmentation index 0.237* 0.035
Central augmentation pressure (mmHg) 0.247* 0.028
Central SBP (mmHg) 0.157 0.167
Central DBP (mmHg) 0.004 0.973
Central pulse pressure (mmHg) 0.210 0.065
SBP (mmHg) 0.111 0.331
DBP (mmHg) 0.006 0.957
Pulse pressure (mmHg) 0.128 0.261
MAP (mmHg) 0.155 0.172
hsCRP (mg/l) 0.015 0.900
Creatinine (mmol/l) 0.066 0.565
BUN (mmol/l) 0.041 0.717
spKt/V 0.075 0.509
Hemoglobin (g/l) 0.109 0.341
Calcium (mmol/l) 0.042 0.714
Phosphate (mmol/l) 0.159 0.161
Alkaline phosphatase (IU/l) 0.074 0.520
Sodium (mmol/l) 0.083 0.465
Potassium (mmol/l) 0.095 0.405
Total cholesterol (mmol/l) 0.244* 0.037
LDL cholesterol (mmol/l) 0.049 0.680
HDL cholesterol (mmol/l) 0.139 0.245
Triglyceride (mmol/l) 0.141 0.235
Albumin (g/l) 0.083 0.471
BMI, body mass index; SBP systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea
nitrogen; LDL-cholesterol, low-density lipoporotein cholesterol; HDL-cholesterol, high-density lipoprotein
cholesterol; iPTH, intact parathyroid hormone.
*P < 0.05 is considered statistically significant.
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Table 4. Outcome measures of cardivascular events, cardiovascular mortality and all-cause mortality in hemodialysis patients
Select baseline parameters
Outcome measures
Cardiovascular events Cardiovascular mortality All-cause mortality
no yes no yes no yes
n 69 25 63 11 63 31
age (years) 63.09 ± 14.4* 70.5 ± 12.1 61.6 ± 14.5** 73.4 ± 8.3 61.6 ± 14.5*** 71.9 ± 10.6
BMI (kg/m2) 26.2 ± 5.3 28.3 ± 7.3 26.8 ± 6.1 27.3 ± 7.9 26.8 ± 6.1 26.7 ± 5.6
augmentation index 30.01 ± 9.3 30.6 ± 12.6 29.6 ± 10.1 32.2 ± 13.3 29.6 ± 10.1 31.2 ± 10.5
pulse wave velocity (m/sec) 7.8 (7; 9.3) 7.7 (6.3; 8.7) 7.7 (6.6; 8.8) 8.6 (7.8, 9.5) 7.7 (6.6; 8.8) 8.2 (7.2; 9.2)
systolic blood pressure (mm/Hg) 140 (120; 150) 140 (120; 145) 140 (120; 150) 120 (100; 160) 140 (120; 150) 140 (120; 150)
diastolic blood pressure (mm/Hg) 80 (60; 80) 80 (60; 80) 80 (70; 80) 80 (60, 80) 80 (70; 80) 80 (60; 80)
urea nitrogen (mmol/l) 20 ± 5.5 17.8 ± 3.8 20.4 ± 5.4* 17.1 ± 2.6 20.4 ± 5.4** 17.6 ± 4.1
creatinine (mmol/l) 695.8 ± 201.1 650.4 ± 230.6 713.5 ± 221.5 635.5 ± 138.5 713.5 ± 221.5* 623.2 ± 168.5
hemoglobin (g/l) 11.6 (11; 12.3) 11.4 (10.7; 12.3) 11.5 (11.1; 12.3) 11.2 (10.5; 11.9) 11.5 (11.1; 12.3) 11.6 (10.6; 12.4)
albumin (g/l) 41.8 (32.7; 43.5) 39.3 (38.6; 42.2) 42.1 (38.7; 43.9) 38.9 (38; 40.1) 42.1 (38.7; 43.9) 38.9 (37.2; 41.8)
parathyreoid hormon (pmol/l) 29.9 (16.1; 42.2) 26.9 (15.1; 66.2) 30.8 (17.4; 48.2) 20.5 (13.4; 30.4) 30.8 (17.4; 48.2) 21.4 (13.4; 39.2)
calcium (mmol/l) 2.33 (2.21; 2.43) 2.24 (2.18; 2.41) 2.36 (2.2; 2.46)** 2.19 (2.14; 2.22) 2.36(2.2; 2.46)** 2.24 (2.16; 2.28)
phosphate (mmol/l) 1.6 ± 0.4 1.6 ± 0.5 1.7 ± 0.7 1.5 ± 0.5 1.7 ± 0.5* 1.5 ± 0.4
vitamin D3 (nmol/l) 15.2 (8.3; 28.5)
* 7.8 (7.5; 15) 16.7 (7.7; 29)** 7.8 (7.5; 10.2) 16.7(7.7; 29)** 8.8 (7.5, 15.2)
fetuin-A (g/l) 0.45 ± 0.13* 0.39 ± 0.1 0.45 ± 0.1* 0.37 ± 0.1 0.45 ± 0.1 0.42 ± 0.14
a-Klotho protein (pg/ml) 314.1 ± 135.6* 257.6 ± 79.5 304.6 ± 118.9* 227.3 ± 82.3 304.6 ± 118.9 287.9 ± 138.9
hsCRP (mg/l) 5.4 (1.7; 11.2) 6.4 (2.1; 12.8) 3.6 (1.4; 10.3) 8.4 (3.9; 11.3) 3.6 (1.4; 10.3)** 8.2 (5.2; 15)
TNFa (pg/ml) 21.3 (16.2; 37.9) 18.8 (14.3; 38.2) 20.2 (15.9; 39.9) 18.5 (12.8; 21.6) 20.2 (15.9; 39.9) 21.3 (14.5; 37.4)
TGF-b1 (ng/ml) 0.65 (0.4; 1.14) 0.98 (0.55; 4.16) 0.69 (0.42; 1.4) 0.74 (0.51; 3.2) 0.69 (0.42; 1.4) 0.68 (0.42; 1.3)








Our present study confirmed that the pro-inflammatory cascade of AS was activated and inflam-
matory biomarkers (hsCRP, TNF-a, TGF-b1) prevailed over protective factors (vitamin D, a-Klotho,
Fetuin-A) in patients on HD. We demonstrated that cfPWV as a measure of AS was significantly
affected by total cholesterol, fetuin-A and dialysis time; all other variables studied had no apparent
impact on stiffness parameters. Importantly, several clinical and laboratory factors were associated
with pro- and anti-inflammatory biomarkers rather than with AS, underlining the complexity of the
relationship between uremic environment, low-grade inflammation and cardiovascular health.
When select baseline parameters were analyzed at the end of the follow-up period of three
years, adverse cardiovascular outcomes were found to be associated with significantly decreased
vitamin D, a-Klotho protein and fetuin-A levels. All-cause mortality was strongly related to
vitamin D depletion and elevated hsCRP.
Inflammation
The crucial role of inflammation in the initiation and progression of cardiovascular diseases is well
established [9]. Expression of pro-inflammatory cytokines has been shown in all cell types involved in
the pathogenesis of AS, and they have been claimed to be responsible for the cross-talk among endo-
thelial, smoothmuscle cells, leukocytes andother vascular residing cells [10]. Recently a newconcept has
emerged contending that independent of typical inflammation, inflammasome activationmay serve as a
basic mechanism to mediate and promote the progression of cardiovascular diseases. Accordingly,
inflammasome activation may cause endothelial dysfunction and injury, stimulation of myofibroblast
proliferation and differentiation with enhanced synthesis of collagen and other extracellular matrix
proteins, as well as it may trigger and amplify the inflammatory response of leukocytes [11].
Patients on HD have pro-inflammatory condition and the severity of inflammation corre-
lates with VS [12]. Compelling evidences have been provided to indicate a singificant association
between VS and increased cardiovascular morbidity and mortality in patients with chronic renal
disease [13] and in those receiving HD [12]. VS is widely used as a measure of this association
and PWV has been shown to be higher in patients on HD than in healthy controls. Moreover, its
increase over time in ESRD patients exceeds the age-related increase in the healthy population,
indicating that vascular ageing is accelerated by ESRD [14, 15].
In our study AC was not assessed directly but an attempt was made to reveal the association
of stiffness parameters with markers of inflammation. Surprisingly, both the Alx and cfPWV
proved to be independent of pro-inflammatory (hsCRP, TNF-a, TGF-b1) and anti-inflamma-
tory (vitamin D, fetuin-A, a-Klotho) biomarkers. However, inflammation per se was signifi-
cantly influenced by several clinical and laboratory variables of uremia. These include vitamin D
deficiency, hyponatraemia, hypoalbuminaemia, plasma creatinine, dialysis time, BMI and age.
Vitamin D
We paid particular attention to defining the possible role of protective mechanisms that may
attenuate the vascular damage. Vitamin D deficiency has emerged as a cardiovascular risk-
factor. Beneficial interaction has been described between vitamin D and CRP, interleukins and
anti-inflammatory cytokines [16], and it has been demonstrated to improve endothelial function
[17] and to inhibit VSMC proliferation [18].
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In spite of available evidences for cardiovascular protection by vitamin D, metaanalyses of
randomized controlled clinical trials expressed concern about the impact of vitamin D deficiency
on cardiovascular health. To reconcile the conflicting results the concept has emerged that the
association between vitamin D levels and cardiavascular morbidities is U-shaped and there is a
therapeutic window that should be considered when vitamin D is administered [19]. Most
recently Qi et al. have claimed that biomarkers of vitamin D status beyond 25(OH) vitamin D
(vitamin D-binding protein and parathyorid hormon) may have an independent and synergistic
association with the risk of cardiovascular diseases [20]. In our study population an apparent
vitamin D deficiency was documented that was associated with adverse cardiavascular outcomes
and all-cause mortality and was related to inflammation (hsCRP) rather than VS.
a-Klotho
The role of a-Klotho protein in the progression of arteriosclerotic processes is also a subject of
controversies. It was identified as an anti-ageing factor but was subsequently discovered to have
multiple biological actions including cytoprotection mediated by anti-inflammation, anti-
oxidation and anti-apoptosis [21, 22].
It has been reported that the renal expression of Klotho mRNA is markedly reduced in
patients with CRF [23], and a low level of circulating a-Klotho has been detected in patients on
HD, but this has not been associated with cardiovascular diseases [24]. On the other hand, there
are studies indicating that soluble Klotho protects against uremic cardiomyopathy [25], and
Klotho upregulation ameliorates VC in patients with CRF [26]. With this contention in line
haplodeficiency of Klotho gene causes arterial stiffening [27].
Our present study confirmed previous observations of depressed soluble Klotho levels in
patients on regular HD, but failed to detect their association with VS. The positive relationship
of a-Klotho to TNF-a may be regarded as indicating an adaptive elevation of a-Klotho to
mitigate inflammatory reaction.
Fetuin-A
Our further purpose was to assess possible vasculo-protection by fetuin-A. Fetuin-A is a
multifunctional protein that plays a critical role in a variety of metabolic and vascular diseases
including obesity, diabetes mellitus type 2, metabolic syndrome and atherosclerosis [13]. It acts
as an antagonist of members of the TGF-b superfamilies, suppresses TNF-a release from
macrophages and inhibits calcification by forming soluble mineral complexes [28, 29].
Inconsistent data have been reported on the involvement of fetuin-A in the development of
the vascular pathologies of chronic renal diseases. The inconsistencies are supposed to be due to
the biphasic response pattern of plasma fetuin-A during the course of the disease. In advanced
stage fetuin-A levels are decreased and inversely related to VS as evaluated by PWV [30]. The
low levels may be accounted for by its reduced production and/or its consumption to form
fetuin-mineral complex. In the early stage of chronic renal disease fetuin-A is upregulated to
provide protection against pro-inflammatory, pro-calcific stress [31]. In agreement with this
notion, in our HD patients fetuin-A correlated positively with PWV.
In view of the conflicting data on the role fetuin-A in ESRD patients on HD, we line up with
those who think that using this biomarker in clinical practice is presently unwarranted [32].
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Study limitations
Only a limited number of HD patients were included and we did not have enough age-matched
control participants, thus the selection bias cannot be excluded. Only a few individual bio-
markers were selected and measured. To get further insight into the pathomechanism of
vascular damage in ESRD, proteomic and/or metabolomic studies are to be conducted.
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